10-Q: Candel Therapeutics Reports Q2 2024 Financial Results and Provides Clinical Program Update

Candel Therapeutics reports a net loss of $30.5 million for the first half of 2024, while highlighting positive clinical data for its lead product candidates.

Summary

• Candel Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, reporting a net loss of $22.2 million for the quarter and $30.5 million for the first six months of the year.
• The company's cash and cash equivalents stood at $21.5 million as of June 30, 2024.
• Candel is focused on developing off-the-shelf viral immunotherapies, with lead product candidates CAN-2409 and CAN-3110 currently in clinical trials.
• The company has incurred recurring losses since its inception, including a net loss of $30.5 million for the six months ended June 30, 2024, and has an accumulated deficit of $167.5 million.
• The company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future.
• Substantial doubt exists about the company's ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.
• The company expects to finance its cash needs through a combination of public or private equity or debt financings, government grants, and other sources.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical data updates and regulatory designations, the company's financial situation is concerning, with substantial losses and doubts about its ability to continue as a going concern. This results in a negative overall sentiment.

Positives

• CAN-2409 demonstrated promising clinical activity in NSCLC and pancreatic cancer, with significant improvements in overall survival compared to standard treatments.
• CAN-3110 showed encouraging survival data in recurrent HGG patients, with evidence of immune activation and tumor responses.
• The FDA granted fast track and orphan drug designations for both CAN-2409 and CAN-3110, which may expedite their development and regulatory review.
• The company's enLIGHTEN Discovery Platform is generating novel viral immunotherapy candidates with promising preclinical data.

Negatives

• The company has incurred significant operating losses and has an accumulated deficit of $167.5 million as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's cash and cash equivalents were $21.5 million as of June 30, 2024, which is expected to fund operations only into the first quarter of 2025.
• The company is dependent on raising additional capital to fund its operations and may be forced to delay, reduce, or eliminate some of its research, clinical trials, product development, or future commercialization efforts if it is unable to do so.
• The company's warrant liability increased significantly, resulting in a $13.3 million expense for the six months ended June 30, 2024.

Risks

• The company has a limited operating history and has not generated any revenue from product sales.
• The company's business is dependent on the success of CAN-2409, CAN-3110, and any other product candidates that it advances into the clinic.
• The company's preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of its product candidates.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• The company has incurred indebtedness, and may incur additional indebtedness, which could adversely affect its financial condition.
• The company's rights to develop and commercialize certain of its product candidates are subject to the terms and conditions of licenses granted to it by third parties.
• The company's manufacturing operations are dependent on third-party contract manufacturers, which may result in delays or expenses.
• Any future public health crisis, outbreaks of an infectious disease, or ongoing geopolitical conflicts may have adverse effects on the company's business and operations.

Future Outlook

The company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future and will require additional funding to sustain operations beyond the first quarter of 2025. The company expects to finance its cash needs through a combination of public or private equity or debt financings, government grants, and other sources.

Management Comments

• Management believes that viral immunotherapy is among the most promising cancer treatment modalities today.
• Management expects that research and development expenses will continue to increase substantially for the foreseeable future.
• Management has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.

Industry Context

The company operates in the competitive biopharmaceutical industry, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and research organizations. The company's focus on viral immunotherapies places it in a rapidly evolving field with both opportunities and challenges.

Comparison to Industry Standards

• The reported median overall survival of 20.6 months for CAN-2409 in NSCLC patients with progressive disease despite ICI therapy is a significant improvement compared to the published median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population (Reckamp K et al. J Clin Onc 2022;40:2295-2306).
• The estimated median overall survival of 28.8 months in the CAN-2409 group versus only 12.5 months in the control group in borderline resectable PDAC is a notable improvement compared to standard of care.
• The median overall survival of 11.8 months in arm A and 12.0 months in arm B for CAN-3110 in recurrent HGG patients is promising, considering the poor prognosis of this patient population with expected overall survival < 6-9 months.

Management Changes

Related Party Transactions

• The company has an exclusive licensing agreement with Ventagen, LLC, an entity owned in part by certain of the company's stockholders.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential future restructuring or workforce reductions.
• Patients may benefit from the development of new therapies, but also face risks associated with clinical trials.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company expects to report topline data for the phase 3 and phase 2 clinical trials of CAN-2409 in prostate cancer in the fourth quarter of 2024.
• The company expects to present updated overall survival data for CAN-2409 in NSCLC and PDAC in the first quarter of 2025.
• The company expects to share updated phase 1b data from the patients in cohort 1/arm C for CAN-3110 in recurrent HGG in the second half of 2024.

Key Dates

Keywords

viral immunotherapy, cancer, CAN-2409, CAN-3110, clinical trials, biopharmaceutical, immunotherapy, prostate cancer, NSCLC, pancreatic cancer, recurrent HGG, FDA, orphan drug designation, fast track designation